EMA suspends licence for ingenol mebutate (Picato)

Drug Ther Bull. 2020 Apr;58(4):51. doi: 10.1136/dtb.2020.000012. Epub 2020 Mar 4.

Abstract

Overview of: Medicines and Healthcare products Regulatory Agency. Ingenol mebutate gel (Picato▼): suspension of the licence due to risk of skin malignancy. Drug Safety Update 2020;13(7):1.

Keywords: adherence; adverse effects.